These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28655469)

  • 1. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
    Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 9-Phenanthrol enhances the generation of an CD8
    Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
    J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
    Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
    Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
    Stein P; Gogoll K; Tenzer S; Schild H; Stevanovic S; Langguth P; Radsak MP
    PLoS One; 2014; 9(7):e102664. PubMed ID: 25025233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
    Stein P; Rechtsteiner G; Warger T; Bopp T; Fuhr T; Prüfer S; Probst HC; Stassen M; Langguth P; Schild H; Radsak MP
    J Invest Dermatol; 2011 Jan; 131(1):211-9. PubMed ID: 20739947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.
    Stein P; Weber M; Prüfer S; Schmid B; Schmitt E; Probst HC; Waisman A; Langguth P; Schild H; Radsak MP
    PLoS One; 2011; 6(11):e27911. PubMed ID: 22114725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization.
    Gogoll K; Stein P; Lee KD; Arnold P; Peters T; Schild H; Radsak M; Langguth P
    Cell Immunol; 2016 Oct; 308():35-43. PubMed ID: 27318760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
    Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
    Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
    Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
    J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.
    Klavinskis LS; Whitton JL; Oldstone MB
    J Virol; 1989 Oct; 63(10):4311-6. PubMed ID: 2476571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells efficiently induce protective antiviral immunity.
    Ludewig B; Ehl S; Karrer U; Odermatt B; Hengartner H; Zinkernagel RM
    J Virol; 1998 May; 72(5):3812-8. PubMed ID: 9557664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
    Hartmann AK; Bartneck J; Pielenhofer J; Meiser SL; Arnold-Schild D; Klein M; Stassen M; Schild H; Muth S; Probst HC; Langguth P; Grabbe S; Radsak MP
    Front Immunol; 2023; 14():1238861. PubMed ID: 37727790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.
    Hany M; Oehen S; Schulz M; Hengartner H; Mackett M; Bishop DH; Overton H; Zinkernagel RM
    Eur J Immunol; 1989 Mar; 19(3):417-24. PubMed ID: 2468501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice.
    van der Most RG; Murali-Krishna K; Whitton JL; Oseroff C; Alexander J; Southwood S; Sidney J; Chesnut RW; Sette A; Ahmed R
    Virology; 1998 Jan; 240(1):158-67. PubMed ID: 9448700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CCR7 on priming and distribution of antiviral effector and memory CTL.
    Junt T; Scandella E; Förster R; Krebs P; Krautwald S; Lipp M; Hengartner H; Ludewig B
    J Immunol; 2004 Dec; 173(11):6684-93. PubMed ID: 15557160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus.
    Moskophidis D; Zinkernagel RM
    J Virol; 1995 Apr; 69(4):2187-93. PubMed ID: 7533851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors.
    Dell K; Koesters R; Gissmann L
    Int J Cancer; 2006 Jan; 118(2):364-72. PubMed ID: 16052529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.
    Sedlik C; Dadaglio G; Saron MF; Deriaud E; Rojas M; Casal SI; Leclerc C
    J Virol; 2000 Jul; 74(13):5769-75. PubMed ID: 10846055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice.
    Holst PJ; Christensen JP; Thomsen AR
    J Immunol; 2011 Apr; 186(7):3997-4007. PubMed ID: 21357263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.